Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 AF-0901 (midazolam) in convulsive status epilepticus (≥15 years)
jRCT2080224539Phase 3Completed
- Sponsor
- Alfresa
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midazolam in status epilepticus (SE), sponsored by Alfresa. Primary endpoint: Convulsive seizure cessation. Started Jan 2019; status: completed.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on jRCT2080224539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224539.